Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Anacor Appoints CEO | Contract Pharma
Breaking News, Promotions & Moves

Anacor Appoints CEO

Berns brings more than 20 years of industry experience

Paul L. Berns has been appointed president and chief executive officer Anacor Pharmaceuticals, Inc. Mr. Berns previously served as Anacor’s chairman of the board of directors. Mr. Berns succeeds David P. Perry who has served as president and chief executive officer since 2002.
 
Mr. Berns has more than 20 years of industry experience having held executive roles in the pharma and biopharma industries. He most recently served as the president and chief executive officer of Allos Therapeutics.
 
“We appreciate David’s commitment to Anacor and the many contributions he has made over the past 12 years to help build Anacor into the company it is today,” said Paul Klingenstein, chair of the nominating and governance committee of the Anacor board. “We are delighted to have attracted a proven leader of Paul’s capabilities to assume the role of CEO for the next phase of Anacor’s growth. Having served as Chairman, Paul has a deep knowledge of Anacor’s management team, strategy, partners and development pipeline, thus enabling a smooth transition. Additionally, Paul’s significant commercial and product development experience, combined with his strategic and business development expertise, makes him ideally suited to lead Anacor as we seek to achieve our goals.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters